期刊
CLINICAL ONCOLOGY
卷 27, 期 8, 页码 460-464出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2015.04.033
关键词
Breast cancer; CNS metastases; HER2 positive; radiotherapy
类别
资金
- Anglo-Celtic trials group
- Cancer Research UK [C973/A9894, C19480/A6379]
- Cancer Research UK [15960] Funding Source: researchfish
A high incidence of central nervous system (CNS) metastases has been reported in patients with HER2-positive tumours receiving trastuzumab therapy for metastatic breast cancer. This study tested whether prophylactic cranial irradiation (PCI) could reduce the incidence of CNS metastases in this setting. This was a prospective, randomised phase III trial. Patients were randomised 1:1 to no PCI or PCI delivered at around 6 weeks after study entry. Cognitive function was assessed prospectively. In total, 51 patients were randomised over a 3 year period; 25 received PCI and 26 did not. The cumulative incidence of CNS metastases at 2 years was 32.4% (standard error = 9.8%) on the no PCI arm and 21.0% (standard error = 8.6%) on the PCI arm; the associated hazard ratio was 0.57 (95% confidence interval 0.18-1.74; P = 0.32). There was no evidence of cognitive dysfunction in PCI patients. Crown Copyright (C) 2015 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据